You searched for "endothelium"

421 results found

Cataract surgery in small adult eyes

This is a retrospective audit of a five year study period, between the periods of January 2006 to December 2010, where a surgical log book search was performed. The inclusion criteria of this study were intraocular lenses (IOL) power greater...

Microbial keratitis in corneal grafts

The authors report a retrospective case series of 59 episodes of microbial keratitis identified in 41 eyes of 41 patients (39 penetrating keratoplasty (PKPs) and two deep anterior lamellar keratoplasty (DALKs)), from a total of 759 consecutive corneal grafts identified...

Ranibizumab safety in pregnancy

Vascular endothelial growth factor (VEGF) plays a pivotal role during pregnancy, and systemic anti-VEGF administration during this period should thus be avoided. VEGF is expressed in multiple embryonic and foetal tissues during development, with the highest levels found in the...

Rebound phenomenon after IVT triamcinolone acetonide for macular oedema

In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...

Evaluation of Optive® in ocular discomfort after anti-VEGF intravitreal injection

In this study the authors prospectively evaluated the efficacy of Optive® eye drops after in full, then abbreviation - intravitreal injection (IVT). Patients naïve to IVT were included in the study. No artificial tear treatment was prescribed after the first...

Comparison of the efficacy of anti-VEGFs agents in nvAMD

This retrospective multicentric study conducted in Israel and Canada, compared the efficacy of bevacizumab, aflibercept 2mg and ranibizumab as first-line treatments for neovascular age-related macular degeneration (nvAMD). Included were treatment-naïve nvAMD eyes receiving ≥12 months of treat-and-extend (T&E) anti-VEGF therapy...

Belfast Eye Conference 2024

by Zina Mobarak, FY1 Doctor, Manchester University Foundation Trust, UK. The Belfast Eye conference was held online over two days, aimed at anyone interested in ophthalmology and focused on delivering informative talks from specialists in various ophthalmic specialties and presenting...

When the chatbot gets it wrong: Navigating AI-generated health misinformation in ophthalmology

Patients are beginning to turn to large language model chatbots for healthcare information. As clinicians, we are not only required to know when they are wrong, but why they are wrong – and what we can do about it. Recently,...

Surgical options for the treatment of hyperopia

The modern refractive surgeon has a variety of options available to treat patients with hyperopia who wish to be independent of spectacles and contact lenses. Unlike in low myopia where presbyopic patients may have the ability to see well for...

Ciliatech reports positive clinical results on novel glaucoma implant, CID, in 24-month post-operative follow up

Chavanod (near Annecy), France, March 29, 2023 - Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, announced the positive results of a 24-month post-operative follow-up on a clinical trial of CID, its first generation Cilio-scleral Inter-positioning Device.

Therapy for limbal stem cell deficiency: cell fate after limbal stem cell transplants

“The beauty of scientific research lies in that the search for answers often yields yet more questions.” A large body of evidence points to the corneoscleral limbal location as the repository of putative epithelial stem cells [1]. Thoft proposed the...

Boosting key protein in eye cells could prevent age-related vision loss, international team finds

Increasing the levels of a key protein in the cells at the back of the eye could help protect against the leading cause of vision loss among older adults, finds a new discovery made by researchers from the UK, US, Germany and Australia.